David A. Fidock

This study designs and tests depeptidized boronic acid inhibitors of PfSUB1, finding improved potency but needing further optimization for membrane permeability.

The paper identifies potent reaction hijacking inhibitors targeting Plasmodium falciparum asparagine tRNA synthetase, showing high selectivity and resistance refractoriness.

This study identifies divergent resistance mechanisms in Plasmodium HSP90 inhibitors despite shared binding sites, showing that enhanced binding can paradoxically correlate with resistance.

The paper identifies pfcrt copy number amplification as a new antimalarial resistance mechanism in Plasmodium falciparum and develops a TaqMan assay for its detection.

This study shows that CHIR-124, a human Chk1 inhibitor, is active against Plasmodium falciparum through dual inhibition of PfArk1 and hemozoin formation, suggesting polypharmacology as a strategy for antimalarial drugs.

This study identifies a mutation in PfAQP and duplication of superoxide dismutase genes as mechanisms of resistance to cryptosporin in Plasmodium falciparum.

This study identifies a novel K13 double mutation conferring resistance to ozonide antimalarials in Plasmodium falciparum parasites with existing artemisinin resistance.

This study identifies new antimalarial compounds targeting PfATP4 through phenotypic screening, showing fast-killing activity and resistance patterns consistent with PfATP4 inhibition.

This paper develops a recombinant Pf20S platform for structural analysis and inhibitor design, identifying a selective inhibitor with high potency against Plasmodium falciparum proteasome.

This study uses CRISPR/Cas9 to knockout plasmepsin II and III in Cambodian malaria parasites, showing increased sensitivity to piperaquine and linking plasmepsin gene copy numbers to PPQ resistance.

This study compares gametocyte production and transmission fitness of ART-sensitive and ART-resistant P. falciparum isolates across multiple mosquito species.

This study identifies quinoxaline-based anti-schistosomal compounds with potent anti-malarial activity against Plasmodium falciparum, including resistance mechanisms involving pfqrp1 and pfatp2.

This study identifies DMT1 and a chromosome 12 locus, including FtsH1, as novel contributors to Plasmodium falciparum resistance to quinine, alongside the known pfcrt gene.

The paper identifies mixed alkyl/aryl phosphonates as anti-malarial compounds that inhibit serine hydrolases with low resistance potential.

The paper identifies genetic determinants of multidrug resistance in Plasmodium falciparum and their impact on parasite fitness and drug susceptibility.

This study examines changes in genome organization during the transmission stages of Plasmodium parasites and finds that three-dimensional genome structure is linked to transcriptional activity of gene families involved in pathogenesis and immune evasion.

Whole genome sequencing reveals how Plasmodium falciparum evolves resistance to diverse compounds and identifies new antimalarial drug targets.